A carregar...
Should FOLFOXIRI Plus Bevacizumab Be the Standard First-Line Therapy in Metastatic Colorectal Cancer?
The TRIBE trial compared the FOLFOXIRI regimen plus bevacizumab with FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. FOLFOXIRI plus bevacizumab is an acceptable therapeutic option, but the results of the TRIBE trial do not establish this regimen as the best treatment option f...
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AlphaMed Press
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4350810/ https://ncbi.nlm.nih.gov/pubmed/25660156 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0495 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|